ANNOUNCEMENT 15 Apr 2014

In April 2014, the government of the Russian Federation announced a change in private-sector financial support.

NUMBER OF INTERVENTIONS

1

  • 0 harmful
  • 1 neutral
  • 0 liberalising

SOURCE

Decree N305 of the Government of Russian Federation dated 15 April 2014.
http://pravo.gov.ru/proxy/ips/?docbody=&prevDoc=102441384&backlink=1&&nd=102349191
Complete text of the state program for the development of the pharmaceutical and medical industries in the period 2013-2020, available at the Internet site of the Ministry of Industry of the Russian Federation, http://www.minpromtorg.gov.ru/ministry/fcp/pharma_and_medical_industry

Inception date: 03 Nov 2012 | Removal date: open ended
Still in force

Financial grant

On 15 April 2014, the Russian Government approved the state program "Development of the Pharmaceutical and Medical Industries in 2013-2025". The stated goal of the program is to assist the development of innovative domestic pharmaceutical and medical manufacturing by strengthening R&D, technological and manufacturing potential of the Russian pharmaceutical and medical manufacturers, as well as horizontal measures targeting improved IT systems and human resource development.

The Program's four sub-programs cover, respectively, the manufacturing of medicines, the manufacturing of medical devices and items, development of IT infrastructure and human resources and the grandfathered pre-2013 sectoral development program.

The Program is coordinated by the Ministry of Industry and Trade, and has a budget allocation of 93 billion rubles (USD 2.6b at April 2014 exchange rate) spread over 8 years. Half of the total eight-year budget is reserved to the grandfathered sectoral program, around a third is allocated to pharmaceuticals production.  

Government support is to be instrumentalized through direct subsidies to manufacturers of (a) pharmaceuticals and (b) medical items, covering the set-up of new productions, clinical trial expenses, purchase of equipment, substances, and government-sponsored R&D.

AFFECTED SECTORS